Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats

Hypertension
Y IzumiH Iwao

Abstract

To examine chronic changes in mitogen-activated protein (MAP) kinases in cardiac hypertrophy, we determined the activities of two subfamilies of MAP kinases, including extracellular signal-regulated kinases (ERKs) and c-Jun NH2-terminal kinases (JNKs), in the heart of stroke-prone spontaneously hypertensive rats (SHRSP) and Wistar-Kyoto rats (WKY) aged 5, 8, 14, and 24 weeks. MAP kinases were determined by using in-gel kinase assay. In both the left and right ventricles of WKY, the activities of ERKs (p44ERK and p42ERK) and JNKs (p46JNK and p55JNK) decreased significantly with age, indicating that aging remarkably downregulated cardiac MAP kinase activities. In SHRSP, left ventricular ERK and JNK activities were already significantly higher at the mild hypertensive phase than they were in the same age of WKY, and they remained higher until development of left ventricular hypertrophy. On the contrary, the right ventricle of SHRSP, which did not exhibit cardiac hypertrophy, had no significant increase in ERK or JNK activities compared with WKY, except for the slight increase in p55JNK in 24-week-old SHRSP. Antihypertensive treatment of SHRSP with imidapril, an angiotensin-converting enzyme inhibitor, decreased the left ventricula...Continue Reading

References

Nov 24, 1995·Science·Z XiaM E Greenberg
Jul 14, 1995·The Journal of Biological Chemistry·M Karin
Nov 1, 1994·Trends in Biochemical Sciences·R J Davis
May 12, 1994·Nature·J M KyriakisJ R Woodgett
Apr 1, 1993·Trends in Biochemical Sciences·E Nishida, Y Gotoh
Apr 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I KomuroY Yazaki
Jun 15, 1996·The Journal of Clinical Investigation·E TeigerP Hamet
Oct 4, 1996·The Journal of Biological Chemistry·J M Kyriakis, J Avruch

❮ Previous
Next ❯

Citations

May 12, 2000·Alimentary Pharmacology & Therapeutics·K TominagaT Kuroki
Jul 14, 2010·Antioxidants & Redox Signaling·Jakob Vinten-JohansenKarin Przyklenk
Jan 2, 2003·Molecular and Cellular Biology·Felix B EngelRüdiger von Harsdorf
Dec 13, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shinji TakaiMizuo Miyazaki
Apr 5, 2007·Journal of Molecular and Cellular Cardiology·Jason N PeartGarretta J Gross
Jun 5, 2003·Acta Physiologica Scandinavica·R P Taylor, J W Starnes
Nov 19, 2003·Journal of Cellular Biochemistry·Ashakumary LakshmikuttyammaRajendra K Sharma
Oct 27, 2007·Redox Report : Communications in Free Radical Research·Vladimir VinokurMordechai Chevion
Aug 27, 2009·Acta Physiologica Hungarica·H R CrossCharles Steenbergen
Dec 11, 1999·Journal of Molecular and Cellular Cardiology·Y TakemotoJ Yoshikawa
May 12, 2005·American Journal of Physiology. Renal Physiology·Chun-Fang XiaJulie Chao
Jun 19, 2001·American Journal of Physiology. Heart and Circulatory Physiology·M El MabroukE L Schiffrin
Jun 21, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Grant BledsoeJulie Chao
Feb 17, 2021·Pflügers Archiv : European journal of physiology·Charia McKeeXun Ai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.